Satellos Bioscience Inc. (MSLE:NASDAQ) closed at $6.42 on October 23, 2026, down 3.09% on the day. The stock trades 52.1% below its 52-week high of $13.40 and 21.0% above its 52-week low of $5.30. Over the past year, it gained 0.2%. Satellos Bioscience Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, MSLE closed higher on 106 days (42%). Its best day was June 25, 2026 (+19.40%) and its worst was March 10, 2026 (-18.11%). The stock moved 10% or more in a single session 16 times. It opened at least 5% above the previous day's high 7 times.
Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of helping restore muscle stem cell signaling that is disrupted in DMD. By addressing the loss of dystrophin-dependent cues, SAT-3247 may re-establish the signals that support effective muscle regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment, initially for DMD. Satellos is also working to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities.
Find more stocks like MSLE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.